Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 124Multiple Myeloma 84Precursor Cell Lymphoblastic Leukemia-Lymphoma 76Lymphoma 73Lymphoma, Non-Hodgkin 66Leukemia 66Myelodysplastic Syndromes 56Hodgkin Disease 53Lymphoma, Large B-Cell, Diffuse 37Lymphoma, Mantle-Cell 33Breast Neoplasms 32Neuroblastoma 30Leukemia, Lymphocytic, Chronic, B-Cell 30Burkitt Lymphoma 30Lymphoma, Follicular 26Leukemia, Myelogenous, Chronic, BCR-ABL Positive 26Recurrence 24Sarcoma 18Neoplasms, Plasma Cell 18Hematologic Neoplasms 18Central Nervous System Neoplasms 18Lymphoma, B-Cell, Marginal Zone 17Leukemia, Biphenotypic, Acute 16Myeloproliferative Disorders 15Lymphoma, Large-Cell, Immunoblastic 15Congenital Abnormalities 15Brain Neoplasms 14Leukemia, Myelomonocytic, Chronic 13Anemia, Refractory, with Excess of Blasts 13Medulloblastoma 12

Interventions

Gemcitabine 2Docetaxel 2pegfilgrastim 1pazopanib 1ixabepilone 1Thalidomide 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrent Uterine Corpus Sarcoma × Granulocyte Colony-Stimulating Factor × Clear all
NCT00031629 2016-12-08

Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus

GOG Foundation

Phase 2 Completed
51 enrolled
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡